Innovative respiratory inhaler Airflusal® Forspiro® receives Alufoil Trophy 2015
April 16, 2015 - AirFluSal® Forspiro®, an innovative respiratory inhaler from Sandoz, has won the coveted Alufoil Trophy 2015 in the Product Preservation category. The inhaler uses a specially designed alufoil blister strip, which was developed by Amcor Flexibles, that ensures a longer shelf life of the inhalation powder.
This recognition for technical innovation is the second award for AirFluSal® Forspiro®. In 2011, the device received the Red Dot Product Design Award, an internationally recognized quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany, for innovative product design.
“We are proud and delighted to accept the Alufoil Trophy for AirFluSal® Forspiro® in the Product Preservation category, together with our collaboration partner Amcor,” said Jan-Torsten Tews, Global Head, Respiratory Franchise at Sandoz International. “This novel approach to improving the entire patient experience shows that true innovation in this field is not just about ‘frontline’ design, but also about rethinking the whole packaging development process to optimize product efficacy and quality.”
The Alufoil Trophy, presented annually by the European Aluminium Foil Association (EAFA), recognises and rewards the use of aluminium foil and aluminium closures in all its many forms and uses.
Sandoz, a division of Novartis, is a global leader in generic pharmaceuticals, driving sustainable access to high-quality healthcare. Sandoz employs more than 26,000 people worldwide and supplies a broad range of affordable, primarily off-patent products to patients and customers around the globe. The Sandoz global portfolio comprises approximately 1,100 molecules, which accounted for 2014 sales of USD 9.6 billion. Sandoz holds the global #1 position in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines. In addition, Sandoz holds leading global positions in key therapeutic areas ranging from generic injectables, dermatology and respiratory to cardiovascular, metabolism, central nervous system, pain and gastrointestinal. Sandoz develops, produces and markets finished dosage form (FDF) medicines as well as intermediary products including active pharmaceutical ingredients (APIs) and biotechnological substances. Nearly half of Sandoz's portfolio is in differentiated products – products that are scientifically more difficult to develop and manufacture than standard generics. In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has consistently driven growth in selected geographies and differentiated product areas through a series of targeted acquisitions, including Hexal (Germany), EBEWE Pharma (Austria), and Fougera Pharmaceuticals (US).
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global.
For further information
Sandoz Global Communications:
+49 8024 476 2550
Sandoz Global Communications:
+49 8024 476 1906